Carbapenem-resistant Enterobacterales (CRE) are extensively drug resistant organisms (XDROs) that have few treatment options and high mortality rates. CRE are increasingly detected among patients in Illinois, including in acute and long term care healthcare facilities.
In response to the CRE public health threat, the Illinois Department of Public Health (IDPH) has guided development of an infection control tool called the XDRO registry. The purpose of the XDRO registry is two-fold:
- Improve CRE surveillance: The first CRE-positive culture per patient stay must be reported to the XDRO registry.
- Improve inter-facility communication: Healthcare facilities can query the XDRO registry to see whether a patient has been previously reported as CRE-positive.
For access to the XDRO registry, click here
UPDATES
- NEW! XDRO registry training: [Quick Videos] [FAQs]
- CRE are reportable to IDPH via the XDRO registry. Links: [IDPH letter to facilities, September 2013] [Reporting rule] [Slides]
- IDPH is also entering Candida auris (as of January 2017), carbapenemase-producing Pseudomonas aeruginosa (April 2017), and carbapenem-resistant Acinetobacter baumannii cases (June 2019) into the XDRO registry.
- Guidance on control of multidrug-resistant organisms (MDROs): [CDC CRE and MDROs] [CDC C. auris] [AHRQ CRE toolkit] [IDPH Detect and Protect Campaign]
- As of November 1, 2013, the XDRO registry is open for CRE submissions and queries.